Practitioner 2012; 256 (1751): 11-12

Are newer anticoagulants as cost-effective as warfarin?

22 May 2012Registered users

An economic evaluation, based on modelling, has suggested that dabigatran may be a cost-effective first-line treatment for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF) in the UK.

Registered usersThis article can only be accessed if you are a registered user of thepractitioner.co.uk or a subscriber to The Practitioner.